Robust clinical evidence supports the FDA’s regulatory clearance. The approval was backed by data from six clinical studies involving over 600 participants. The trials demonstrated high accuracy across various physiological ranges and proved that the sensor could effectively flag clinically meaningful deviations in ketone levels well before the formal onset of DKA.

Looking ahead to clinical integration, this device marks a major step toward building safer, automated healthcare ecosystems. Abbott has established a new “integrated continuous glucose-ketone” (iCGK) standard, paving the way for immediate and future interoperability.

The manufacturer plans a U.S. commercial rollout later this year, with automated insulin delivery (AID) pump integrations expected to follow shortly.

Compatibility with Beta Bionics’ iLet and Sequel Med Tech’s twiist systems is slated by the end of this year, followed by Tandem, Insulet, and Medtronic integrations on the horizon.

As you prepare to counsel people with diabetes on this new technology, it is important to reinforce that ketone trends must always be interpreted alongside concurrent glucose data and physical presentation.

The introduction of the Libre Duo provides an unprecedented opportunity to safely optimize therapeutic regimens, promote self-management confidence, and drastically reduce the costly economic and emotional burden of DKA.